产品
编 号：F056146
分子式：C28H34N6O5
分子量：534.61
分子式：C28H34N6O5
分子量：534.61
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1176758-04-5
产品详情
生物活性：
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury.
体内研究：
Otaplimastat (10-20 mg/kg; i.p. 30 min before occlusion and 1 h after reperfusion) prevents ischemic neuronal death in the occlusion model of MCA.Otaplimastat (5-10 mg/kg; i.p. daily for 10 days) attenuates impairment of stroke-induced motor function.Animal Model:Male Wistar rats (280-310 g, 9 weeks) were induced transient middle cerebral artery (MCA) occlusion
Dosage:10, 20 mg/kg
Administration:I.p. before 30 min and after an hour of the MCA-occlusion operation
Result:Significantly reduced infarct volume.Improved spatial learning and memory impairments.
体外研究：
Otaplimastat (87.5-350 μM; 20 min) protects neuronal cells against NMDA-induced cell death in a competitive manner.Otaplimastat (350 μM) inhibits Ca2+ influx following activation of NMDA receptors in primary cultured neuron.Otaplimastat (2-200 μM; pretreated for 4 h) significantly suppresses H2O2-induced cell death and reactive oxygen species production.
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury.
体内研究：
Otaplimastat (10-20 mg/kg; i.p. 30 min before occlusion and 1 h after reperfusion) prevents ischemic neuronal death in the occlusion model of MCA.Otaplimastat (5-10 mg/kg; i.p. daily for 10 days) attenuates impairment of stroke-induced motor function.Animal Model:Male Wistar rats (280-310 g, 9 weeks) were induced transient middle cerebral artery (MCA) occlusion
Dosage:10, 20 mg/kg
Administration:I.p. before 30 min and after an hour of the MCA-occlusion operation
Result:Significantly reduced infarct volume.Improved spatial learning and memory impairments.
体外研究：
Otaplimastat (87.5-350 μM; 20 min) protects neuronal cells against NMDA-induced cell death in a competitive manner.Otaplimastat (350 μM) inhibits Ca2+ influx following activation of NMDA receptors in primary cultured neuron.Otaplimastat (2-200 μM; pretreated for 4 h) significantly suppresses H2O2-induced cell death and reactive oxygen species production.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备